Learn More
See You Virtually,
for ASVAC 2022!
Following a major success in 2019, the biennial 8th Asian Vaccine Conference is set to return virtually.
Organised by the Immunisation Partners in Asia Pacific (IPAP), the theme of ASVAC 2022 is ‘IMMUNISATION IN THE ERA OF PANDEMICS’.
ASVAC 2022 aims to provide participants unparalleled insights into the latest research, vaccine developments and treatments in the field of vaccine-preventable diseases and immunisation through its comprehensive scientific programme led by regional vaccinology experts.
Join us for an enriching experience and expert insights on the practice and future of vaccinology. We look forward to welcoming you at ASVAC 2022!
Download the Programme and Abstract Book
PROGRAMME OVERVIEW
The Programme below is based on IST time (GMT +5.30)
| Timing (IST / GMT +5.30) |
PRE-CONGRESS: 16 Sept 2022, Friday | |
|---|---|---|
| ASAP Symposium: Updates on Pneumococcal Vaccines Development Chair: Lulu C. Bravo (Philippines) Zulkifli Ismail (Malaysia) |
HPV Workshop Chair: Kirthini Muralidharan (United States of America) |
|
| 0800 - 1030 hrs | Egemen Ozbilgili (Pfizer)Olakunle Oladehin (GSK)Jin Oh Kim (MSD)Nitin Shah | Daniel Chulwoo Rhee (United States of America)Didik Setiawan (Indonesia)Kurnia Eka Wijayanti (Indonesia) |
| VACCINOLOGY MASTERCLASS : ASVAC 2022 | ||
| 1030 - 1040 hrs | Welcome AddressDaniel Goh (Singapore) | |
| 1040 - 1100 hrs | History & Impact of VaccinationMathu Santhosham (United States of America) | |
| 1100 - 1220 hrs | Basic Vaccine Immunology | |
| 1100 - 1120 hrs | How & Why Vaccines Work: Basics of Immune Responses and Mechanisms of VaccinesPhilippe Buchy (Singapore) | |
| 1120 - 1140 hrs | Fundamentals of Vaccine Clinical DevelopmentAlberta Di Pasquale (Singapore) | |
| 1140 - 1200 hrs | Importance of Disease Surveillance in Vaccination StrategiesPhilippe Buchy (Singapore) | |
| 1200 - 1220 hrs | Concept of Cross-Protection and Herd ImmunityJin Oh Kim (South Korea) | |
| 1220 - 1230 hrs | Break | |
| 1230 - 1300 hrs | Communications - Addressing Vaccine HesitancyZulkifli Ismail (Malaysia) | |
| 1300 - 1500 hrs | Vaccination through the Ages - Vaccines in Each Stage of Life | |
| 1300 - 1330 hrs | Vaccination in InfantsElizabeth Gallardo (Philippines) | |
| 1330 - 1400 hrs | Vaccination in AdolescentsPramod Jog (India) | |
| 1400 - 1430 hrs | Vaccination in PregnancySybil Bravo (Philippines) | |
| 1430 - 1500 hrs | Vaccination in ElderlyJean-Pierre Michel (Switzerland) | |
| 1500 - 1530 hrs | Clinical ApplicationH.T. Wickramasinghe (Sri Lanka) Rajiva de Silva (Sri Lanka) |
|
| 1530 - 1550 hrs | Vaccines: What Lies in the Future?Jerome Kim (South Korea) | |
| 1550 - 1600 hrs | Concluding RemarksDaniel Goh (Singapore) | |
| 1600 hrs | End of Pre-Congress Programme | |
The Programme below is based on IST time (GMT +5.30)
| Timing (IST / GMT +5.30) |
DAY 1: 17 Sept 2022, Saturday | |
|---|---|---|
| Stream 1 | Stream 2 | |
| 0830 - 0840 hrs | Welcome AddressLulu C. Bravo (Philippines) | |
| 0840 - 0850 hrs | Introduction to ASVAC 2022H.T. Wickramasinghe (Sri Lanka) | |
| 0850 - 0900 hrs | Opening MessageKeheliya Rambukkwella (Hon. Minister of Health, Sri Lanka) | |
| 0900 - 0930 hrs | Plenary Lecture 1 Chair: Lulu C. Bravo (Philippines) |
|
| Equity and COVIDKim Mulholland (Australia) | ||
| 0930 - 1045 hrs | Symposium 1: Vaccines through the AgesPartners: International Federation of Aging |
Symposium 2: Respiratory VaccinesPartners: Asia Pacific Alliance for the Control of Influenza (APACI) |
| Chair: Susie Perera (Sri Lanka) | Chair: Neelika Malavige (Sri Lanka) | |
| 0930 – 0950 hrs | Implementing Life Course Immunisation Schedules: What Needs to be DoneJane Barret (Canada) | Flu Vaccine UpdatesPushpa Ranjan Wijesinghe (India) |
| 0950 – 1010 hrs | Pregnancy & missed opportunitiesSybil Bravo (Philippines) | Pneumococcal Disease PreventionChiu Cheng Hsun (Taiwan) |
| 1010 – 1030 hrs | Travel VaccinesPornthep Chanthavanich (Thailand) | Respiratory Syncytial Virus (RSV)Lien Anh Ha Do (Australia) |
| Q&A | Q&A | |
| 1045 - 1145 hrs | Industry Symposia 1: AstraZeneca COVID-19 Vaccine Effectiveness: Myths vs RWE. Are Current Vaccines Optimal to Protect the Most Vulnerable? |
Industry Symposia 2: GSK Healthy Aging: Vaccines For Life |
| Chair: Bruce Mungall (Singapore) | Chair: H.T. Wickramasinghe (Sri Lanka) | |
 |
 |
|
|
Expert Global Review of COVID-19 Vaccine Effectiveness: Booster Doses Versus OmicronAnna Ong-Lim (Philippines) Third and Fourth Dose Effectiveness of COVID-19 Vaccines in Chiang Mai, ThailandSuwat Chariyalertsak (Thailand) The Unmet Need in High-Risk Groups Despite Vaccination: Leaving No- One BehindBarnaby Young (Singapore) |
Burden of VPDs in Adults & ElderlyGeorge Kassianos (United Kingdom) Advancement in Vaccinology: Increasing Vaccine Effectiveness in Adults & ElderlySelim Badur (Turkey) |
|
| 1145 - 1300 hrs | Symposium 3: COVID Vaccines |
Symposium 4: Communication and Advocacy |
| Chair: BJC Perera (Sri Lanka) | Chair: Dineshani Hettiarachchi (Sri Lanka) | |
|
COVID-19 Vaccinations for Children: Following the EvidenceBen Cowling (Hong Kong) "Special Population Groups” - Cancer Patients on Chemo, Transplant Patients, Dialysis Patients and Patients with Immune DeficiencyNeelika Malavige (Sri Lanka) Routine Childhood Immunizations During COVIDAnna Ong-Lim (Philippines) |
Latest Strategies to Communicate Vaccine SafetyPramod Jog (India) Communicating Impact of COVID on Childhood ImmunisationLois Privor (United States) Immunisation Agenda 2030: Geneva Learning FoundationCharlotte Mbuh (Switzerland) The Ethics of Challenge Studies to Fast Track Vaccine DevelopmentJulian Savulescu (United Kingdom) |
|
| Q&A | Q&A | |
| 1300 - 1330 hrs | Plenary Lecture 2 Chair: Tony Nelson (China) |
|
| Bats, Viruses and PandemicsLinfa Wang (Singapore) | ||
| 1330 - 1415 hrs | Panel 1: Pooled Procurement - Lessons Learned during COVID and Future OpportunitiesPartners: National Vaccine Institute, UNICEF |
Panel 2: Vaccine Confidence in the Asia Pacific RegionPartners: APAC Coalition |
Chair: Tony Nelson (China) |
Chair: Daniel Goh (Singapore) Lulu C. Bravo (Philippines) |
|
|
ASEAN Initiatives for Pooled ProcurementNakorn Premsri (Thailand) UNICEF's Pooled Procurement MechanismAndrew Jones (Denmark) |
Zulkifli Ismail (Malaysia) |
|
| 1415 - 1515 hrs | Industry Symposia 3: Takeda Takeda Dengue Symposium: Latest Update on Dengue |
Industry Symposia 4: Sanofi Sustaining Immunization for Children in the Current Era |
| Chair: Puneet Kalra (India) | Chair: Anna Ong-Lim (Philippines) | |
 |
 |
|
|
Current Status of Dengue in Sri Lanka and Asian CountriesNeelika Malavige (Sri Lanka) Clinical Managment of DengueA. LakKumar Fernando (Sri Lanka) Brief Overview of Takeda Dengue Vaccine (TAK -003) with 4.5 year data resultsVianney Tricou (Switzerland) |
Addressing the Challenges of Increasing Immunization Rates with Combination VaccinesFederico Martinon Torres (Spain) Global Polio Eradication Initiative: Role of wP Combination containing IPV vaccineMouloud Khris (Morocco) |
|
| 1515 hrs | End of Day 1 Programme | |
The Programme below is based on IST time (GMT +5.30)
| Timing (IST / GMT +5.30) |
DAY 2: 18 Sept 2022, Sunday | |
|---|---|---|
| Stream 1 | Stream 2 | |
| 0900 - 0930 hrs | Plenary Lecture 3 Chair: Zulkifli Ismail (Malaysia) |
|
| Priority Vaccines for Developing World (Malaria, HIV)Peter Hotez (United States of America) | ||
| 0930 - 1045 hrs | Symposium 5: Enteric VaccinesPartners: ROTA Council/ PATH/ IVI |
Symposium 6: Unfinished Business |
| Chair: Shaman Rajindrajith (Sri Lanka) | Chair: Jennifer Perera (Sri Lanka) | |
| 0930 – 0950 hrs | Cholera Vaccine LandscapeJulia Lynch (South Korea) | HPV Vaccine Updates: Evidence towards Use of Single DoseDaniel Chulwoo Rhee (United States of America) |
| 0950 – 1010 hrs | Typhoid Vaccines: Experience from Early IntroducersAziza Mwisongo (United States of America) | Dengue Vaccine UpdatesOoi Eng Eong (Singapore) |
| 1010 – 1030 hrs | Current Status Oral Rotavirus VaccinesCarl Kirkwood (United States of America) | PolioSomia Iqtadar (Pakistan) |
| 1030 – 1045 hrs | Q&A | Q&A |
| 1045 - 1145 hrs | Industry Symposia 5: MSD Challenges and Prospects of Pneumococcal Prevention in Adults Within Asia Pacific Chair: Rontgene Solante (Philippines) |
|
 | ||
| Key Considerations in Pneumococcal Prevention in Adult Population and Future ProspectsPaul Van Buynder (Australia) | ||
| Challenges and Prospects of Pneumococcal Prevention in Adults in the Asia Pacific RegionTerapong Tantawichien (Thailand) | ||
| 1145 - 1155 hrs | FREE PAPER SESSION A Chair: Dilini Nakkawita (Sri Lanka) |
FREE PAPER SESSION B Chair: A. H. Hazari (Sri Lanka) |
| Vaccines in Development: Immunogenicity and Safety of Hexavalent DTwP-IPV-HB-PRP~T Vaccine Compared With Licensed Pentavalent DTwP-HB-PRP~T Vaccine in Healthy Infants In Thailand: A Phase III Randomized StudyLeilani Sanchez (Philippines) | Disease-Specific Vaccines: Correlation Between Patient-reported and Clinician-assessed Symptoms and Case Definition to Capture Moderate- to-Severe RSV Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b StudyEsther Heijnen (United States of America) | |
| 1155 - 1205 hrs | Disease-Specific Vaccines: Effectiveness of COVID-19 vaccine booster doses against Omicron-related serious diseaseRontgene Solante (Philippines) | Monitoring and Surveillance: Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand.Suwat Chariyalertsak (Thailand) |
| 1205 - 1215 hrs | Vaccines in Development: Antibody Persistence After Primary Series With DTwP-IPV-HB-PRP~T Compared With Separate DTwP-HB-PRP~T and IPV Vaccines, and Booster Response to DTwP-IPV-HB-PRP~T in Healthy Toddlers in IndiaSomnath Mangarule (India) | Targeted Vaccination Strategies: Literature review on the knowledge, attitude and practice regarding herpes zoster and zoster vaccination in Asia-PacificJing Chen (Singapore) |
| 1215 - 1225 hrs | Disease-Specific Vaccines: IgG antibody response among recipients of the ChAdOx1 nCoV-19 Vaccine: A single center experience from Sri LankaDhanuka Dhanaratna (Sri Lanka) | Evidenced-based Introduction of New Vaccines: Capturing the value of vaccination within health technology assessment and health economics - Literature review and novel conceptual frameworkYu-Fan Ho (Singapore) |
| 1225 - 1235 hrs | Disease-Specific Vaccines: Regimen Selection and 1.5-year Immunogenicity Evaluation of Prophylactic Ad26.RSV.preF Vaccine Combinations: A Randomised, Double-Blind, Placebo-Controlled, Adaptive Design Phase 1/2a Study in Adults Aged ≥60 YearsArangassery Rosemary Bastian (United States of America) | Monitoring and Surveillance: Covid 19 Immunization Tracking in low resource setting using Opensource information systemsGumindu Kulatunga (Sri Lanka) |
| 1235 - 1245 hrs | Vaccines in Specific Settings: Evaluation of immunity against hepatitis B virus infection and factors associated with anti-HBs levels among vaccinated haemodialysis patients at two major Nephrology-Units in Sri LankaMohamed Asmir (Sri Lanka) | Targeted Vaccination Strategies: The epidemiology and cost of dengue disease in Sri Lanka: a systematic literature reviewJing Shen (Switzerland) |
| 1300 - 1330 hrs | Plenary Lecture 4Chair: Dhanushka Dasanayake (Sri Lanka) | |
| The Next Pandemic - Are We Prepared?Paul Anantharajah Tambyah (Singapore) | ||
| 1330 - 1415 hrs | Panel 3: Meet the Vaccine ExpertsPartners: Philippine Foundation for Vaccines, IPAP, APPA, Immunise for Life (Malaysia) Chair: Lulu C. Bravo (Philippines) |
|
| Rose Capeding (Philippines) Piprim (Indonesia) Zulkifli Ismail (Malaysia) Usa Thisyakorn (Thailand) |
||
| 1415 - 1445 hrs | Closing Plenary LectureChair: Kim Mulholland (Australia) | |
| Vaccines: What Does the Future Hold?Jerome Kim (South Korea) | ||
| 1445 - 1515 hrs | Prize Presentation IPAP & Organising Chair of ASVAC 2023 Speech Closing CeremonyLulu C. Bravo (Philippines) | |
Disclaimer: The Organising Committee may, in its discretion, amend any part of the programme without prior notice.
Platinum Sponsors
Organised by
Hosted by
Managed by
